Effect of cyclosporin A on the proliferation activity of mesenchymal stem cells

( views:, downloads: )
Author:
WANG Yon-ling(Department of Hematology, the Second Hospital of Shanxi Medical University, Yaiyuan 030001, China)
QIAO Zhen-hua(Department of Hematology, the Second Hospital of Shanxi Medical University, Yaiyuan 030001, China)
CHOU Li-xia()
GONG Rong()
JIA Qing-yun()
CHU De-qing()
NIU Bo()
Journal Title:
JOURNAL OF LEUKEMIA & LYMPHOMA
Issue:
Volume 19, Issue 03, 2010
DOI:
10.3760/cma.j.issn.1009-9921.2010.03.013
Key Word:
Myelodysplastic syndromes;Cyclosporin h4 Mesenchymal stem cells;Cell proliferation

Abstract: Objective To provide data for reference on the impact of cyclosporin A (CsA) on the proliferation of the bone marrow mesenchymal stem cells in MDS patients through the investigation of the impact of cyclosporin A on human bone marrow mesenchymal stem cell proliferation. Methods The absorption rates of the bone marrow mesenchymal stem cells in the control group and the MDS patient group were determined by using the tetrazolinm salt (MTT) micro-colorimetric enzyme reaction. The concentrations of cyclosporine A are 2.5×10~4 ng/μl, 2.5×10~3 ng/μl, 2.5×10~2 ng/μl and 2.5×10ng/μl respectively. Results There is no significant difference between the each result by using different concentrations of CsA., which indicates the impact of CsA on the growth of mesenchymal stem cells is not significant(P >0.05). In the serial of concentrations mentioned, no cytotoxicity of CsA is observed. However, there is difference between the selected indicators of the control group and the patient group (P <0.01), and the value of the MDS patient group is higher than that of the control group. There is no statistic difference between the concentration of CsA and the data obtained from interactions between different groups (P >0.05). There is no significant difference between the absorption rates of the group treated by CsA of every concentration and the corresponding control group. Conclusion The impact of CsA on the bone marrow mesenchymal stem cell proliferation is significant in neither healthy people nor MDS patients.

  • [1]Deeg HJ.Marrow stroma in MDS:culprit or bystander? Leuk Res,2002,26:687-688.
  • [2]郭晓椭,徐世荣,任会海,等.用环孢菌素A联合方案治疗骨髓增生异常综合征.临床血液学杂志,2001,14:150-152.
  • [3]何广胜,王秀丽,吴德沛.骨髓增生异常综合征的诊断.实用医技杂志,2009,9:669-673.
  • [4]肖志坚.WHO(2008)骨髓增生异常综合征诊断标准.国际输血及血液学杂志,2009,32:109-110.
  • [5]Samuelsson J,Larfars G,Unusual clinical presentation in a patient with myelodysplastic syndrome with subsequent hematological remission and suppression of the malignant clone following treatment with cyclosporine A erythropoietin and granulocyte colonystimulating factor.Leuk Res,1999,23:513-517.
  • [6]Shimamoto T,Ohyashiki K.Immunosuppressive treatments for myelodysplastic syndrome.Leuk Lymphoma,2003,44:593-604.
  • [7]张翼,达万明.骨髓增生肄常综合症患者间充质干细胞的生物学特性及体外支持造血的实验研究.中国实验血液学杂志,2005,13:839-842.
  • [8]王莉,张伟京,李秀森,等.细胞毒药物对小鼠肺组织和骨组织间充质干细胞增殖和分化的影响.中国组织工程研究与临床康复,2009,32:6279-6283.
  • [9]曾赞,孙载阳,姜藻.环孢菌素A在细胞凋亡中的作用.东南大学学报(医学版),2001,20:137-139.
  • [10]任翠爱,张茂宏,徐从高,等.环孢菌素A治疗对再生障碍件贫血患者骨髓细胞凋亡的影响.中华血液学杂志,2001,22:189-192.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn